Combination therapies are superior to monotherapy for many cancers. This advantage was
historically ascribed to the ability of combinations to address tumor heterogeneity, but …

Signaling networks play key homeostatic processes in living organisms but are commonly
hijacked in oncogenesis. Prominent examples include genetically altered receptor tyrosine …

Evidence has recently emerged that many clinical cancer drug combinations may derive
their efficacy from independent drug action (IDA), where patients only receive benefit from …

It is becoming increasingly evident that cancers are dependent on a number of altered
molecular pathways and can develop diverse mechanisms of resistance to therapy with …

Combination cancer therapies aim to improve the probability and magnitude of therapeutic
responses and reduce the likelihood of acquired resistance in an individual patient …

Current cancer therapy includes a variety of strategies that can comprise only one type of
treatment or a combination of multiple treatments. Chemotherapy is still the gold standard for …

Gene products or pathways that are aberrantly activated in cancer but not in normal tissue
hold great promises for being effective and safe anticancer therapeutic targets. Many …

Cancer chemotherapy treatments typically employ drug combinations in which the dose of
each agent is pushed to the brink of unacceptable toxicity; however, emerging evidence …

The rapid development of new therapeutic agents that target specific molecular pathways
involved in tumour cell proliferation provides an unprecedented opportunity to achieve a …

The majority of diseases are associated with alterations in multiple molecular pathways and
complex interactions at the cellular and organ levels. Single-target monotherapies therefore …